| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 05/16/2000 | US6063385 Veterinary medicine |
| 05/16/2000 | US6063380 Enhanced immunogenic vaccine |
| 05/16/2000 | US6063379 Anti-idiotypic monoclonal antibodies and compositions including the anti-idiotypic monoclonal antibodies |
| 05/16/2000 | US6063375 Semiallogeneic cell hybrids and related methods for treating cancer |
| 05/16/2000 | CA2131826C Mn gene and protein |
| 05/16/2000 | CA2065286C Treatment of chronic inflammatory conditions |
| 05/13/2000 | CA2289329A1 A suppressive agent against expression of cell adhesion molecules |
| 05/13/2000 | CA2289327A1 An anti-edema agent |
| 05/12/2000 | CA2288680A1 Modulation of cell proliferative disorders by cyclic rgd |
| 05/11/2000 | WO2000026667A1 Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein ib alpha |
| 05/11/2000 | WO2000026418A1 Human pan-hcv human monoclonal antibodies |
| 05/11/2000 | WO2000026407A1 Method for determining cancer by determining expression of mage-10 |
| 05/11/2000 | WO2000026394A1 Variants of humanized anti-carcinoma monoclonal antibody cc49 |
| 05/11/2000 | WO2000026384A1 Lps with reduced toxicity from genetically modified gram negative bacteria |
| 05/11/2000 | WO2000026380A1 Rotavirus subunit vaccine |
| 05/11/2000 | WO2000026379A2 Polypeptide mediating cell permeability |
| 05/11/2000 | WO2000026376A1 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 05/11/2000 | WO2000026375A2 Nucleic acids and polypeptides specific of the neisseria genus pathogenic strains |
| 05/11/2000 | WO2000026374A2 Adipose specific protein |
| 05/11/2000 | WO2000026360A1 Compounds and methods for modulating claudin-mediated functions |
| 05/11/2000 | WO2000026250A1 HUMAN H37 PROTEINS AND cDNAS ENCODING THE SAME |
| 05/11/2000 | WO2000026240A2 Streptococcal alpha2m-binding protein |
| 05/11/2000 | WO2000026239A2 $i(chlamydia) antigens and corresponding dna fragments and uses thereof |
| 05/11/2000 | WO2000026238A2 Biological materials and methods useful in the diagnosis and treatment of prion diseases |
| 05/11/2000 | WO2000026237A2 Chlamydia 98kd putative outer membrane protein and corresponding dna fragments and uses thereof |
| 05/11/2000 | WO2000026236A2 Method of modulating cell differentiation or neoplastic transformation by altering cadherin-11 expression or function |
| 05/11/2000 | WO2000025831A1 A new composition and method for increasing production yield of agriculturally useful species |
| 05/11/2000 | WO2000025827A2 Dna molecules encoding muc-1 and use thereof in tumor vaccination |
| 05/11/2000 | WO2000025820A1 Compounds and methods for genetic immunization |
| 05/11/2000 | WO2000025817A1 Heparanase activity neutralizing anti-heparanase monoclonal antibody |
| 05/11/2000 | WO2000025816A1 Treatment of hepatitis c by administration of anti-il-2 receptor monoclonal antibody and an antiviral compound |
| 05/11/2000 | WO2000025815A1 Novel immunoadjuvants |
| 05/11/2000 | WO2000025814A2 Component for vaccine against serogroup b meningococci |
| 05/11/2000 | WO2000025813A1 CANCER IMMUNOTHERAPHY AND DIAGNOSIS USING UNIVERSAL TUMOR ASSOCIATED ANTIGENS, INCLUDING hTERT |
| 05/11/2000 | WO2000025812A2 Method for preparing solid phase conjugate vaccines |
| 05/11/2000 | WO2000025811A2 Multicomponent meningococcal vaccine |
| 05/11/2000 | WO2000025808A1 Inhibition of differentiation of cytotoxic t-cells by p-selectin ligand (psgl) antagonists |
| 05/11/2000 | WO2000025807A1 Binding moieties for human parvovirus b19 |
| 05/11/2000 | WO2000025804A2 A method for inhibition of phospholamban activity for the treatment of cardiac disease and heart failure |
| 05/11/2000 | WO2000025728A2 Chromosome 2 sequence of the human malaria parasite plasmodium falciparum and proteins of said chromosome useful in anti-malarial vaccines and diagnostic reagents |
| 05/11/2000 | WO2000025722A2 ENHANCED VACCINES COMPRISING SELF AND NON-SELF IgE PORTIONS OR DIMERIC ANTIGENS |
| 05/11/2000 | WO2000025588A1 Anti-snoring composition |
| 05/11/2000 | WO2000018783B1 Mammaglobin, a secreted mammary-specific breast cancer protein |
| 05/11/2000 | WO2000017344A8 RESPONSE REGULATOR $i(CaSSK1) |
| 05/11/2000 | WO2000009691A3 Bpc-1: a secreted brain specific protein expressed and secreted by prostate and bladder cancer cells |
| 05/11/2000 | WO2000008158A3 Molecules designated ldcam |
| 05/11/2000 | WO2000008043A3 Prevention and treatment of viral disease |
| 05/11/2000 | WO2000007618A3 Anti-apoptotic compositions comprising the r1 subunit of herpes simplex virus ribonucleotide reductase or its n-terminal portion; and uses thereof |
| 05/11/2000 | DE19851282A1 Zusammensetzung einer pharmazeutisch wirksamen Substanz, appliziert in einem spezifischen Delivery-System zur Prävention und Behandlung von Infektions-Krankheiten Composition of a pharmaceutically active substance, applied in a specific delivery system for the prevention and treatment of infectious diseases |
| 05/11/2000 | CA2773380A1 Immunotherapeutic methods using epitopes of wt-1 and gata-1 |
| 05/11/2000 | CA2349758A1 A method for inhibition of phospholamban activity for the treatment of cardiac disease and heart failure |
| 05/11/2000 | CA2349622A1 Heparanase activity neutralizing anti-heparanase monoclonal antibody |
| 05/11/2000 | CA2349504A1 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 05/11/2000 | CA2349495A1 Nucleic acids and polypeptides specific for pathogenic strains of the neisseria genus |
| 05/11/2000 | CA2349331A1 Multicomponent meningococcal vaccine |
| 05/11/2000 | CA2349158A1 Compounds and methods for modulating claudin-mediated functions |
| 05/11/2000 | CA2348960A1 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 05/11/2000 | CA2348958A1 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 05/11/2000 | CA2348777A1 Rotavirus subunit vaccine |
| 05/11/2000 | CA2348756A1 Enhanced vaccines |
| 05/11/2000 | CA2348751A1 Biological materials and methods useful in the diagnosis and treatment of diseases |
| 05/11/2000 | CA2348745A1 Dna molecules encoding muc-1 and use thereof in tumor vaccination |
| 05/11/2000 | CA2348421A1 Protein |
| 05/11/2000 | CA2348285A1 Novel immunoadjuvants |
| 05/11/2000 | CA2348063A1 Method for preparing solid phase conjugate vaccines |
| 05/11/2000 | CA2347119A1 Inhibition of differentiation of cytotoxic t-cells by p-selectin ligand (psgl) antagonists |
| 05/11/2000 | CA2344972A1 Cancer immunotherapy and diagnosis using universal tumor associated antigens, including htert |
| 05/11/2000 | CA2317808A1 Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein ib alpha |
| 05/10/2000 | EP0998582A1 Methods for diagnosis and treating cancers, and methods for identifying pathogenic markers in a sample of normal cells |
| 05/10/2000 | EP0998576A2 Bovine adenovirus type 3 genome |
| 05/10/2000 | EP0998572A2 Aggrecan degrading metallo proteases |
| 05/10/2000 | EP0998569A1 Polynucleotide encoding a polypeptide having heparanase activity and expression of same in transduced cells |
| 05/10/2000 | EP0998567A2 Cloned genomes of infectious hepatitis c viruses and uses thereof |
| 05/10/2000 | EP0998561A1 Trail receptor |
| 05/10/2000 | EP0998559A1 Mammalian secretory peptide-9 |
| 05/10/2000 | EP0998556A2 Diagnosis and treatment of diseases using anti-t-cell receptor vbeta antibodies or peptides which are recognized by said antibodies, and endocrine secretion regulatory protein 1 (esrp1) |
| 05/10/2000 | EP0998493A1 Epitopes of shigella like toxin and their use as vaccine and in diagnosis |
| 05/10/2000 | EP0998305A2 Cytolysis of target cells by superantigen conjugates inducing t-cell activation |
| 05/10/2000 | EP0998302A1 Methods of delaying development of hmfg-associated tumors using anti-idiotype antibody 11d10 |
| 05/10/2000 | EP0998301A1 Nucleic acid based immunotherapy of chronic hepatitis b infection |
| 05/10/2000 | EP0998300A1 Methods and compositions for modulating responsiveness to corticosteroids |
| 05/10/2000 | EP0998298A2 Method of an increasing the antigen presenting ability of monocytes |
| 05/10/2000 | EP0998278A1 Hydroxy and ether-containing oxyalkylene esters and uses thereof |
| 05/10/2000 | EP0494224B1 Use of steroid hormones in compositions for inducing t cell lymphokine production |
| 05/10/2000 | EP0134236B2 Method, porous matrix and device for analytical biospecific affinity reactions |
| 05/10/2000 | CN1252837A Compounds for immunotherapy of prostate cancer and methods for their use |
| 05/10/2000 | CN1252811A Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use as the rapentics |
| 05/10/2000 | CN1252810A Antibody for inhibiting blood coagulation and method of use thereof |
| 05/10/2000 | CN1252809A Modified TNF alpha molecules, DNA encoding such modified TNF alpha molecules and vaccines comprising such modified TNF alpha molecules and DNA |
| 05/10/2000 | CN1252807A Neoglycoproteins |
| 05/10/2000 | CN1252730A Lyme combination compositions and uses |
| 05/10/2000 | CN1252729A Production process for intravenous immune serum globulin and resultant product |
| 05/10/2000 | CN1252712A Use of micro particles having a protein and an antibody adsorbed thereon for preparing a pharmaceutical composition for intranasal administration |
| 05/10/2000 | CN1252408A Serial animal globulin foods and their production process |
| 05/10/2000 | CN1252309A Stabilizer-containing live attenuated hepatitis A vaccine and its preparation |
| 05/10/2000 | CN1252308A Freeze-dried live attenuated hepatitis A vaccine and its preparation |
| 05/10/2000 | CA2287775A1 Attenuated forms of bovine viral diarrhea virus |
| 05/09/2000 | US6060587 Cellular receptor for HIV-1 VPR essential for G2/M phase transition of the cell cycle |
| 05/09/2000 | US6060457 DNA plasmid vaccine for immunization of animals against BVDV |
| 05/09/2000 | US6060308 RNA respiratory syncytial virus vaccines |